Clinical trial of BI 765179 and ezabenlimab in patients with advanced cancer

THE PURPOSE OF THIS STUDY IS TO DETERMINE THE APPROPRIATE DOSE OF BI 765179 WHEN ADMINISTERED ALONE AND WHEN ADMINISTERED IN COMBINATION WITH EZABENLIMAB IN PATIENTS WITH ADVANCED CANCER. THIS IS THE FIRST TIME BI 765179 WILL BE ADMINISTERED TO HUMANS. BI 765179 IS AN INVESTIGATIONAL DRUG THAT MAY TREAT CANCER BY INTERACTING WITH THE IMMUNE SYSTEM. THE IMMUNE SYSTEM IS THE BODY'S NATURAL DEFENSE. THE IMMUNE SYSTEM SENDS CELLS CALLED T-LYMPHOCYTES THROUGHOUT THE BODY TO DETECT AND FIGHT INFECTIONS AND DISEASES, SUCH AS CANCER. BI 765179 IS A BISPECIFIC ANTIBODY (A SPECIAL TYPE OF ANTIBODY THAT HAS 2 BINDING SITES) THAT BINDS TO A PROTEIN ON IMMUNE CELLS CALLED CD137 AND A CANCER PROTEIN CALLED FIBROBLAST ACTIVATION ASSOCIATED PROTEIN (FAP). FAP IS FREQUENTLY FOUND IN MANY TYPES OF CANCER. THE BINDING OF BOTH TARGET SITES CAN ATTRACT T LYMPHOCYTES TO THE TUMOR AND STIMULATE THEM TO ATTACK THE TUMOR CELLS.